Abcam, ab289851, Anidulafungin

Size: 5mg / 25mg
MW 1140.2 g/mol, Purity >95%. Inhibits fungal (1→3)-β-D-glucan synthase. Potent in vitro activity against Aspergillus and Candida species (MIC 50 of 0.03 to 4 μg/ml), including those resistant to fluconazole or amphotericin B. Effective in treating esophageal candidiasis in clinical trials.
Key facts
CAS number:166663-25-8,
Purity:>95%,
Form:SolidSee storage information,
Molecular weight:1140.2 g/mol,
Molecular formula:C58H73N7O17,
Nature:Synthetic,
Solubility:Soluble in DMSO to 5 mM,
Biological description:Inhibits fungal (1→3)-β-D-glucan synthase. Potent in vitro activity against Aspergillus and Candida species (MIC50 of 0.03 to 4 μg/ml), including those resistant to fluconazole or amphotericin B. Effective in treating esophageal candidiasis in clinical trials.,
Canonical smiles:CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O,
InChi:InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1,
InChiKey:JHVAMHSQVVQIOT-MFAJLEFUSA-N,
IUPAC Name:N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide

Product details:
This product is manufactured by BioVision, an Abcam company and was previously called B2966, Anidulafungin. B2966-25 is the same size as the 25 mg size of ab289851.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CYP2C8 also known as Cytochrome P450 2C8 is a member of the cytochrome P450 superfamily of enzymes. It has a molecular mass of approximately 56 kDa. CYP2C8 localizes mainly in the liver but can be found in smaller amounts in other tissues such as the kidney and heart. This enzyme plays a role in oxidizing various substances impacting drug metabolism. The enzyme achieves this by catalyzing reactions involved in drug detoxification and steroid synthesis.
Biological function summary
CYP2C8 facilitates the metabolism of xenobiotics and endogenous compounds contributing to homeostasis. It forms part of the cytochrome P450 hepatic microsomal enzyme complex which contains multiple enzymes responsible for oxidative metabolism. CYP2C8 metabolizes several clinically important drugs including paclitaxel and amodiaquine as well as endogenous arachidonic acid impacting vascular biology.
Pathways
This enzyme acts within the drug metabolism and arachidonic acid metabolism pathways. Within these pathways it works closely with other cytochrome P450 enzymes such as CYP3A4. The drug metabolism pathway requires CYP2C8 for phase I of drug processing which modifies drugs into more water-soluble compounds. In arachidonic acid metabolism CYP2C8 is important to forming bioactive epoxyeicosatrienoic acids that function as signaling molecules in tissues.
Dysregulation of CYP2C8 activity relates to conditions such as drug-induced liver injury and cardiovascular diseases. Variants in the CYP2C8 gene can lead to altered enzyme activity influencing drug response and toxicity. Furthermore its interaction with CYP2C9 in pharmacogenomic variability can affect patients' susceptibility to adverse drug reactions emphasizing the role in personalized medicine approaches.